Multiple 30-Month Stays Remain Possible Under Waxman/Hatch Reforms

Multiple 30-month stays on abbreviated new drug applications are still an option in some cases, an FDA 1draft guidance says

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet